GlassScriptPhysician profile
Steve Heilbrunn
NPI 1700889425
$824.58
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2020: $231 · 2021: $335 · 2022: $112.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $111.81 | 2020-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $107.45 | 2020-2022 | |
| Amgen INC. | $103.49 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $102.86 | 2019-2021 | |
| Abbott Laboratories | $92.57 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $76.12 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $41.02 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $40.06 | 2019-2021 | |
| Esperion Therapeutics, INC. | $31.16 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $30.34 | 2019-2021 | |
| Portola Pharmaceuticals, LLC | $25.57 | 2019 | |
| Pfizer INC. | $19.16 | 2022 | |
| Medtronic Vascular, INC. | $16.05 | 2020 | |
| Amryt Pharma Holdings LTD | $13.81 | 2021 | |
| Amarin Pharma, INC. | $13.11 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steve Heilbrunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.